Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion.

Eggenhofer E, Benseler V, Kroemer A, Popp FC, Geissler EK, Schlitt HJ, Baan CC, Dahlke MH, Hoogduijn MJ.

Front Immunol. 2012 Sep 26;3:297. doi: 10.3389/fimmu.2012.00297. eCollection 2012.

2.

[Distribution and interaction of bone marrow mesenchymal stem cells and cord blood CIK/NK cells infused via different ways at different time periods in NOD/SCID mice].

Li Y, Wang XP, Guo HX, Huang K, Wei J, Zhou DH, Huang WG, Wu YF, Huang SL.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010 Feb;18(1):140-5. Chinese.

PMID:
20137135
3.

The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion.

Gao J, Dennis JE, Muzic RF, Lundberg M, Caplan AI.

Cells Tissues Organs. 2001;169(1):12-20.

PMID:
11340257
4.

Fate and Effect of Intravenously Infused Mesenchymal Stem Cells in a Mouse Model of Hepatic Ischemia Reperfusion Injury and Resection.

Saat TC, van den Engel S, Bijman-Lachger W, Korevaar SS, Hoogduijn MJ, IJzermans JN, de Bruin RW.

Stem Cells Int. 2016;2016:5761487. doi: 10.1155/2016/5761487. Epub 2016 Feb 11.

5.

[A preliminary study of the homing capacity of allograft mesenchymal stem cells to rat liver].

Xiang GA, Zhang GQ, Fang CH, Gao P, Chen KY.

Di Yi Jun Yi Da Xue Xue Bao. 2005 Aug;25(8):994-7. Chinese.

6.

Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells.

Casiraghi F, Azzollini N, Cassis P, Imberti B, Morigi M, Cugini D, Cavinato RA, Todeschini M, Solini S, Sonzogni A, Perico N, Remuzzi G, Noris M.

J Immunol. 2008 Sep 15;181(6):3933-46.

7.

Toward an ideal animal model to trace donor cell fates after stem cell therapy: production of stably labeled multipotent mesenchymal stem cells from bone marrow of transgenic pigs harboring enhanced green fluorescence protein gene.

Hsiao FS, Lian WS, Lin SP, Lin CJ, Lin YS, Cheng EC, Liu CW, Cheng CC, Cheng PH, Ding ST, Lee KH, Kuo TF, Cheng CF, Cheng WT, Wu SC.

J Anim Sci. 2011 Nov;89(11):3460-72. doi: 10.2527/jas.2011-3889. Epub 2011 Jun 24.

8.

Mesenchymal bone marrow cell therapy in a mouse model of chagas disease. Where do the cells go?

Jasmin, Jelicks LA, Koba W, Tanowitz HB, Mendez-Otero R, Campos de Carvalho AC, Spray DC.

PLoS Negl Trop Dis. 2012;6(12):e1971. doi: 10.1371/journal.pntd.0001971. Epub 2012 Dec 13.

9.

Efficiency of endovenous versus arterial administration of mesenchymal stem cells for ischemia-reperfusion-induced renal dysfunction in rats.

Zhuo W, Liao L, Fu Y, Xu T, Wu W, Yang S, Tan J.

Transplant Proc. 2013 Mar;45(2):503-10. doi: 10.1016/j.transproceed.2012.07.162.

PMID:
23498785
10.

Factors that influence short-term homing of human bone marrow-derived mesenchymal stem cells in a xenogeneic animal model.

Kyriakou C, Rabin N, Pizzey A, Nathwani A, Yong K.

Haematologica. 2008 Oct;93(10):1457-65. doi: 10.3324/haematol.12553. Epub 2008 Aug 25.

11.

Dynamic of distribution of human bone marrow-derived mesenchymal stem cells after transplantation into adult unconditioned mice.

Allers C, Sierralta WD, Neubauer S, Rivera F, Minguell JJ, Conget PA.

Transplantation. 2004 Aug 27;78(4):503-8.

PMID:
15446307
12.

Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury.

Tögel F, Weiss K, Yang Y, Hu Z, Zhang P, Westenfelder C.

Am J Physiol Renal Physiol. 2007 May;292(5):F1626-35. Epub 2007 Jan 9.

13.

Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect.

Fischer UM, Harting MT, Jimenez F, Monzon-Posadas WO, Xue H, Savitz SI, Laine GA, Cox CS Jr.

Stem Cells Dev. 2009 Jun;18(5):683-92. doi: 10.1089/scd.2008.0253.

14.
15.

In vivo tracking of 111In-oxine labeled mesenchymal stem cells following infusion in patients with advanced cirrhosis.

Gholamrezanezhad A, Mirpour S, Bagheri M, Mohamadnejad M, Alimoghaddam K, Abdolahzadeh L, Saghari M, Malekzadeh R.

Nucl Med Biol. 2011 Oct;38(7):961-7. doi: 10.1016/j.nucmedbio.2011.03.008. Epub 2011 Jun 22.

PMID:
21810549
16.

Bone marrow mesenchymal stem cells ameliorate hepatic ischemia/reperfusion injuries via inactivation of the MEK/ERK signaling pathway in rats.

Pan GZ, Yang Y, Zhang J, Liu W, Wang GY, Zhang YC, Yang Q, Zhai FX, Tai Y, Liu JR, Zhang Q, Chen GH.

J Surg Res. 2012 Dec;178(2):935-48. doi: 10.1016/j.jss.2012.04.070. Epub 2012 May 18.

PMID:
22658855
17.

Bone marrow-derived mesenchymal stem cells ameliorate hepatic ischemia reperfusion injury in a rat model.

Kanazawa H, Fujimoto Y, Teratani T, Iwasaki J, Kasahara N, Negishi K, Tsuruyama T, Uemoto S, Kobayashi E.

PLoS One. 2011 Apr 29;6(4):e19195. doi: 10.1371/journal.pone.0019195.

18.

Intravenous transplantation of allogeneic bone marrow mesenchymal stem cells and its directional migration to the necrotic femoral head.

Li ZH, Liao W, Cui XL, Zhao Q, Liu M, Chen YH, Liu TS, Liu NL, Wang F, Yi Y, Shao NS.

Int J Med Sci. 2011 Jan 9;8(1):74-83.

19.

Bone marrow mesenchymal stem cells reduce the antitumor activity of cytokine-induced killer/natural killer cells in K562 NOD/SCID mice.

Li Y, Qu YH, Wu YF, Wang XP, Wei J, Huang WG, Zhou DH, Fang J, Huang K, Huang SL.

Ann Hematol. 2011 Aug;90(8):873-85. doi: 10.1007/s00277-011-1156-9. Epub 2011 Jan 15.

PMID:
21234566
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk